zigakibart
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immunoglobulin A Nephropathy (IgAN)
Conditions
Immunoglobulin A Nephropathy (IgAN)
Trial Timeline
Feb 20, 2026 → Oct 18, 2030
NCT ID
NCT07146906About zigakibart
zigakibart is a phase 2 stage product being developed by Novartis for Immunoglobulin A Nephropathy (IgAN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07146906. Target conditions include Immunoglobulin A Nephropathy (IgAN).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07146906 | Phase 2 | Recruiting |
| NCT06858319 | Phase 3 | Recruiting |
Competing Products
11 competing products in Immunoglobulin A Nephropathy (IgAN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| iptacopan | Novartis | Phase 3 | 77 |
| CCX168 | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Rilzabrutinib + Placebo + Glucocorticoid | Sanofi | Phase 3 | 76 |
| rilzabrutinib + Glucocorticoids | Sanofi | Phase 2 | 51 |
| Felzartamab | Biogen | Phase 2 | 49 |
| Felzartamab + Placebo | Biogen | Phase 3 | 74 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| sparsentan + irbesartan + Dapagliflozin | Travere Therapeutics | Phase 3 | 72 |